Our Expertise
At Zin Tech, we bring over 10 years of industry experience in providing cutting-edge IT solutions that help businesses grow. Whether you need web development, mobile apps, or robust security systems, we tailor our services to meet your specific needs and challenges.
Our Leadership
Led by Rashid Hussain, a seasoned software engineer, Zin Tech is driven by a passion for technology and innovation. Rashid’s expertise and vision have been key in establishing Zin Tech as a trusted name in IT solutions.
Our Approach
We believe in a customer-centric approach, taking the time to fully understand your goals and challenges. Our team works closely with you, ensuring that our solutions not only meet your needs but also deliver tangible results that propel your business forward. From web and mobile app development to cybersecurity and cloud services, Zin Tech offers a comprehensive range of IT solutions designed for businesses across various sectors. We prioritize flexibility, ensuring that our solutions evolve with the changing needs of your business.
Commitment to Excellence
With a focus on quality and reliability, we ensure that all projects are delivered on time and within budget. Our dedication to excellence has earned us a reputation for providing innovative, secure, and scalable solutions that empower businesses to thrive in today’s competitive landscape.
Choosing Zin Tech means working with a team of experts who are committed to providing the best IT solutions tailored to your unique business needs. We focus on efficiency, security, and the latest technology to ensure your success.
Research tool
Peptide Reconstitution Calculator
Select your parameters to calculate concentration, draw volume, syringe units, and total doses.
Dose of peptide
Choose the desired amount per dose.
Peptide vial strength
Use the total amount printed on the vial.
Bacteriostatic water
How much water will be added to the vial?
Syringe size
Used to scale the visual guide.
Free reconstitution tool
Peptide Reconstitution Calculator
Enter your vial strength and BAC water volume to get the exact concentration, draw volume, and total doses — instantly.
Peptide vial strength
Total amount printed on the vial label, in mg.
Bacteriostatic water added
Volume of BAC water you inject into the vial, in mL.
Desired dose per injection
Most healing peptides use 100–500mcg. Weight loss peptides use mg doses.
Syringe size
Scales the visual guide. Most peptide users use a 1mL / 100-unit insulin syringe.
Free dosage tool
Peptide Dosage Calculator
Select your dose in mcg or mg, enter your vial strength and BAC water volume. The calculator shows the exact syringe units to draw.
Desired dose
Toggle between mcg and mg, then select your dose. 1mg = 1000mcg.
Peptide vial strength
Total milligrams printed on the vial label.
Bacteriostatic water added
How much BAC water you added when reconstituting the vial, in mL.
Syringe size
Scales the visual guide.
Free blend tool
Peptide Blend Calculator
Calculate draw volumes for 2 or 3 peptides blended into one syringe. Each peptide is calculated from its own reconstituted vial.
Peptide 1
Peptide 2
Peptide 3
For research purposes only. Not medical advice.
BPC-157 Calculator
Calculate the exact syringe units for any BPC-157 dose. Pre-set for the most common research protocols — 250mcg and 500mcg from 5mg and 10mg vials.
BPC-157 Calculator
Pre-set for 250mcg from a 5mg vial with 2mL BAC water. Adjust any value — results update instantly.
Peptide vial strength
Total mg printed on the BPC-157 vial label. Common sizes are 5mg and 10mg.
Bacteriostatic water added
Volume of BAC water you inject into the vial. For BPC-157, 2mL per 5mg vial gives a convenient 2.5mg/mL concentration.
Desired BPC-157 dose
Preclinical research protocols typically use 250mcg or 500mcg per dose. 1mg = 1000mcg.
Syringe size
Scales the visual guide. Most researchers use a 1mL / 100-unit insulin syringe.
What Is BPC-157?
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide — a chain of 15 amino acids — originally derived from a protective protein found in human gastric juice. Unlike most peptides that are rapidly degraded in the gastrointestinal environment, BPC-157 demonstrates remarkable stability in gastric acid, making it one of the few peptides that can be studied in both injectable and oral forms.
The peptide was first identified and characterised by Professor Predrag Sikiric's research group at the University of Zagreb, who have been the primary authors of its preclinical research since the 1990s. Over 100 peer-reviewed studies now document its effects across multiple tissue types, with the most replicated findings in tendon healing, gastrointestinal protection, muscle repair, and angiogenesis.
It is important to note that as of 2024, the FDA classified BPC-157 as a Category 2 substance, restricting its compounding by US pharmacies. All published research is in animal models; no large-scale human clinical trials have been completed. The data supporting its use in humans remains limited to a small number of uncontrolled pilot studies.
Why is it called "157"?
The number refers to its position within the sequence of the parent gastric protein from which it was originally isolated. BPC-157 is a partial sequence of the full body protection compound, selected for its stability and biological activity.
Oral vs injectable BPC-157
Because BPC-157 is stable in gastric acid, it retains some activity when taken orally — which is unusual for peptides. However, most research protocols studying systemic or localised tissue effects use subcutaneous or intramuscular injection, which ensures direct bioavailability without first-pass degradation.
How BPC-157 Works
BPC-157 does not act through a single receptor pathway. It functions as a pleiotropic signalling modulator, influencing three interconnected biological systems that together drive its tissue-repair effects.
VEGFR2-mediated angiogenesis
BPC-157 upregulates vascular endothelial growth factor (VEGF) expression and activates VEGFR2 signalling, stimulating the formation of new capillaries at injury sites. Tendons and ligaments are poorly vascularised by nature — this mechanism is central to why BPC-157 accelerates repair in connective tissue, which normally heals slowly due to poor blood supply.
Growth hormone receptor upregulation
cDNA microarray studies show BPC-157 increases growth hormone receptor (GHR) density on tendon fibroblasts in a dose-dependent manner. Since fibroblasts are the primary cells responsible for collagen synthesis and tissue remodelling, this upregulation enhances the structural repair response — more collagen laid down, faster. GHR expression increased 2.29-fold in treated fibroblasts vs controls.
Nitric oxide system modulation
BPC-157 interacts with the nitric oxide (NO) synthase system, enhancing eNOS (endothelial nitric oxide synthase) activity. Nitric oxide relaxes vascular smooth muscle, improving local perfusion and reducing ischaemia at injury sites. This NO pathway interaction also contributes to BPC-157's documented gastroprotective effects against NSAID and ethanol-induced damage — the most consistently replicated finding in its research literature.
BPC-157 Dosage Guide
The following protocols are drawn from preclinical research literature. BPC-157 has not been approved for human use by any regulatory agency. These figures are for research reference only.
| Protocol | Dose range | Frequency | Route | Typical cycle | Use case in research |
|---|---|---|---|---|---|
| Standard systemic | 250–500mcg | 1–2× daily | Subcutaneous | 4–12 weeks | General tissue repair, gut healing, systemic recovery |
| Low / starting dose | 100–250mcg | 1× daily | Subcutaneous | 4–8 weeks | First-use protocols, sensitivity assessment |
| Localised injection | 250mcg | 1× daily | Intramuscular (near injury) | 4–8 weeks | Tendon, ligament, joint healing — injected proximal to target tissue |
| BPC-157 + TB-500 stack | 250mcg BPC + 2–2.5mg TB-500 | BPC daily · TB-500 2× weekly | Subcutaneous | 6–8 weeks | Soft tissue injury recovery — the most researched combination |
| Weight-adjusted | ~1–10mcg/kg | 1× daily | IP or SC (animal studies) | Varies | Dose range used in the majority of Sikiric group rat models |
How to Reconstitute BPC-157
Allow the vial to reach room temperature
Remove the BPC-157 vial from the freezer or refrigerator 15–30 minutes before reconstitution. A cold vial creates pressure differences when water is injected, which can cause foaming. Room temperature also reduces condensation inside the vial.
Swab both stoppers
Clean the rubber stopper on the BPC-157 vial and the bacteriostatic water vial with a fresh 70% isopropyl alcohol swab. Allow 30 seconds for the alcohol to fully evaporate before inserting any needle — wet alcohol can contaminate the solution.
Draw the calculated BAC water volume
BPC-157 dissolves readily in bacteriostatic water without any acid preparation — unlike some peptides (such as CJC-1295 without DAC) that require dilute acetic acid. Use the reconstitution calculator above to determine your exact water volume before opening anything. The most common protocol: 2mL into a 5mg vial (concentration: 2.5mg/mL), or 2mL into a 10mg vial (concentration: 5mg/mL).
Inject water slowly down the vial wall
Angle the needle so water runs gently down the inner glass wall, not directly onto the lyophilised powder. This prevents mechanical disruption of the peptide structure. Inject slowly over 10–15 seconds. Never push the water in rapidly.
Swirl gently — do not shake
Roll the vial slowly between your palms or tilt it end-to-end. BPC-157 should dissolve to a clear, colourless solution within 30–60 seconds. If powder remains, continue swirling — do not shake. Shaking introduces air bubbles and mechanical agitation that can disrupt peptide bonds. Some sources recommend allowing the vial to rest for 10–20 minutes if any cloudiness persists.
Label the vial immediately
Write the reconstitution date and the BAC water volume used directly on the vial with a permanent marker. These two numbers are essential for every future dose calculation. A 5mg vial reconstituted with 2mL and one reconstituted with 3mL require completely different draw volumes for the same dose.
Bacteriostatic water contains 0.9% benzyl alcohol, a preservative that inhibits bacterial growth across multiple uses. Sterile water has no preservative — it becomes a contamination risk after the first needle insertion and should be discarded within 24–48 hours. For multi-dose research vials of BPC-157, bacteriostatic water is the correct solvent.
BPC-157 storage reference
Common reconstitution concentrations
5mg + 2mL BAC water → 2.5mg/mL
250mcg = 10 units · 500mcg = 20 units
5mg + 3mL BAC water → 1.67mg/mL
250mcg = 15 units · 500mcg = 30 units
10mg + 2mL BAC water → 5mg/mL
250mcg = 5 units · 500mcg = 10 units
10mg + 4mL BAC water → 2.5mg/mL
250mcg = 10 units · 500mcg = 20 units
What the Research Shows
BPC-157 has an unusually large body of preclinical literature for a single compound. The following is a summary of the most replicated and methodologically sound findings. All studies cited are in animal models unless otherwise noted.
Accelerated Achilles tendon repair
Staresinic et al. (2003) demonstrated that BPC-157 significantly accelerated healing of transected Achilles tendons in rat models, with treated tendons showing increased tendon outgrowth, higher ultimate load to failure, and improved functional recovery vs controls. The mechanism involved VEGF-driven angiogenesis increasing capillary density at the repair site.
VEGFR2 activation and new vessel formation
Hsieh et al. (2017) used the chick chorioallantoic membrane (CAM) assay and rat hind limb ischaemia models to show BPC-157 increased vessel density both in vivo and in vitro. Laser Doppler scanning confirmed accelerated blood flow recovery. VEGFR2 and eNOS expression were significantly elevated in treated tissue sections.
Gastroprotection against NSAID and ethanol damage
The most consistently replicated finding in BPC-157 research is its gastroprotective effect. Across dozens of studies since 1993, BPC-157 has been shown to protect against gastric mucosal damage from NSAIDs, ethanol, and stress-induced ulcers in rodent models. This is the original therapeutic context in which the compound was identified.
Multifunctionality review across 12+ organ systems
Jozwiak et al. (2025) published a comprehensive literature and patent review in Pharmaceuticals (MDPI), cataloguing BPC-157 effects across 12 or more organ systems including tendon, gut, liver, CNS, heart, and eye. The review described the evidence base as "unprecedented" in scope for a single peptide, while noting the near-total absence of human clinical trial data.
What the research does not yet show
Over 80% of all published BPC-157 research originates from a single research group (Sikiric et al., University of Zagreb). Independent replication is limited. No large-scale, randomised, double-blind human clinical trials have been completed for any indication. The only human data consists of a small number of uncontrolled pilot studies in approximately 30 subjects total. Whether the preclinical findings translate to humans, at what doses, and with what safety profile, remains unknown.
BPC-157 FAQ
The most common questions about BPC-157 dosage, reconstitution, and calculator use.
For general peptide calculator questions, see the homepage FAQ.
Navigation
Address
- +92 334 8855505
- hello@zin-tech.org
- Head office: 483 E WAPDA Town Phase-1, Multan 60000